ライフサイエンスコーパス: coinfected

1 irrhosis (32 HCV-monoinfected and 65 HIV/HCV-coinfected).

2 tested, 36% (337/947) of IMD cases were HIV-coinfected.

3 fected; Pseudomonas aeruginosa infected; and coinfected.

4 ed by the HCV-monoinfected (19%) and HIV/HCV-coinfected (11%) (P = 0.003 across groups).

5 ide conjugate vaccine, and then sequentially coinfected 5 weeks later with PR8 influenza virus and A6

6 ted a cross-sectional study among 50 HIV/HCV-coinfected, 51 HCV-monoinfected, and 50 HIV-monoinfected

7 in initiators vs nonusers among 7686 HIV/HCV-coinfected, 8155 HCV-monoinfected, 17739 HIV-monoinfecte

8 ess towards elimination goals within HIV/HCV-coinfected adults in Australia following universal DAA a

9 ficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretrovira

10 observational cohort study included HIV/HCV-coinfected adults with genotype 1 HCV who initiated trea

11 atitis B virus (HBV)/hepatitis C virus (HCV) coinfected and 18.2 among HCV monoinfected (P = .03).

12 Contrary to expectations, HIV/HCV-coinfected and HCV-monoinfected adults had significantly

13 ution of baseline characteristics of HIV/HCV-coinfected and HCV-monoinfected patients.

14 urvival time in a large cohort of HIV/HTLV-1-coinfected and HIV-monoinfected individuals on combinati

15 HIV/HCV-coinfected and HIV-monoinfected women had higher median

16 In HIV/HCV-coinfected and HIV-monoinfected women, higher liver stif

17 o significant differences were found between coinfected and monoinfected cases.

18 found in human immunodeficiency virus (HIV)-coinfected and more recently in HIV-uninfected MSM, espe

19 Treatment of coinfected animals with an antihelminthic improved Mtb-s

20 expansion of HTLV-1-infected lymphocytes in coinfected asymptomatic individuals.

21 e defect in the antibody response in infants coinfected being a significantly lower level of anti-gp3

22 and endocarditis in febrile patients who are coinfected by bacteria.

23 Most samples were coinfected by multiple viruses, and the majority of iden

24 iency virus (HIV)-negative cases, HIV type 1-coinfected cases had more prolonged illness, larger lesi

25 In 2025, 92.8% of coinfected cases with loiasis hypermicrofilaremia are pr

26 including human immunodeficiency virus (HIV)-coinfected cases) and rifampicin-resistant tuberculosis.

27 s recessive: genetically mutant progeny from coinfected cells did not display the phenotype.

28 indirect cell-cell interactions prevent most coinfected cells from being completely suppressed by DIP

29 porter expression acquired from thousands of coinfected cells reveal how interference acts at multipl

30 Treatment of coinfected cells with GM-CSF restores bacterial control.

31 ssembly of heterologous gene segments within coinfected cells, and the fitness associated with reasso

32 (i) allows for exchange of gene segments in coinfected cells, termed reassortment, and (ii) necessit

33 These expansions were enhanced in CMV-EBV-coinfected children and were independent of varicella-zo

34 ration of critical drug-drug interactions in coinfected children, as these may significantly impact d

35 A-DR7-restricted CD4(+) T cells from the HIV-coinfected cohort that were specific for epitopes of HCM

36 estimates of recurrence in the high-risk and coinfected cohorts were driven by an increase in reinfec

37 Here we show that in coinfected cultures, AAV2 DNA replication takes place al

38 cific CD4(+) T cells had been activated with coinfected DCs compared to Mtb-infected DCs, and this ef

39 ta, and tumor necrosis factor-alpha, whereas coinfected DCs did not.

40 After coculture with coinfected DCs, M. tuberculosis Ag-specific CD4 T cells

41 In the coinfected group with the same initial count, this rate

42 t statistically nonsignificant among HBV/HCV coinfected (hazards ratio [HR] 1.51; 95% confidence inte

43 o characterize circulating CD4(+) T cells in coinfected HLA-DR7(+) long-term nonprogressor HIV subjec

44 Even if pathogens do not interact, death of coinfected hosts causes net prevalences of individual pa

45 between prevalences means the proportion of coinfected hosts is expected to be higher than multiplic

46 teract, intuition suggests the proportion of coinfected hosts should be the product of the individual

47 we explored if HIV-M. tuberculosis-infected (coinfected) human DCs can dysregulate the M. tuberculosi

48 nhibition of HCV replication in vitro and in coinfected humanized mice also reduced interferon signal

49 une responses warrant further studies in HIV coinfected humans able to control their TB infection.

50 Our study comprised 7229 HIV/HCV-coinfected individuals (68% male, 90% white).

51 erates the progression of HCV disease; thus, coinfected individuals are at high priority for HCV trea

52 iasis prevalence and estimated the number of coinfected individuals at risk of post-ivermectin SAEs i

53 ency virus (HIV) and hepatitis C virus (HCV)-coinfected individuals have declined over the last decad

54 eased transition from latent to active TB in coinfected individuals have not been well elucidated at

55 reported at monthly visits in 3381 HIV/HSV-2-coinfected individuals in a placebo-controlled trial of

56 IL-18 was significantly elevated in coinfected individuals versus both monoinfections (p<0.0

57 where HCV-monoinfected patients and HIV/HCV-coinfected individuals were included if they met: 1) SVR

58 ited generalizability, since the majority of coinfected individuals were not eligible to participate.

59 Genomes of isolate pairs from coinfected individuals were sequenced to determine their

60 d host factors that fuel disease severity in coinfected individuals will help guide the design of eff

61 0% for those with HCV infection, 29.5% among coinfected individuals, and 16.1% for those with neither

62 nterferon-free regimens, particularly in HIV-coinfected individuals, remains unknown.

63 emonstrate enhanced plasma levels of MMPs in coinfected individuals, suggesting a plausible biologica

64 In HIV/HCV-coinfected individuals, the crude incidence of HCC incre

65 important implications for TB control in HIV-coinfected individuals.

66 rogression of inflammatory illnesses seen in coinfected individuals.

67 ts in a multicohort collaboration of HIV/HCV-coinfected individuals.

68 [11 (3.0%) HCV-monoinfected, 8(1.2%) HIV/HCV-coinfected individuals; p=0.013].

69 IgA levels were also significantly lower in coinfected infants 2.5 months postinfection and at the t

70 its use in human immunodeficiency virus/HCV coinfected kidney transplant patients.

71 e treated 6 human immunodeficiency virus/HCV coinfected kidney transplant recipients with ledipasvir-

72 In contrast, independent of transplant era, coinfected LT recipients had increased risk for death (a

73 year, the limited options for treating those coinfected LT recipients with progressive recurrent HCV

74 m tuberculosis/simian immunodeficiency virus-coinfected (M. tuberculosis/SIV-coinfected) macaques to

75 TB risk was not decreased in the coinfected macaques treated with ART for 14-63 days, sug

76 pulmonary CD4(+) T cells was observed in all coinfected macaques, a subpopulation of the animals was

77 ciency virus-coinfected (M. tuberculosis/SIV-coinfected) macaques to model M. tuberculosis/HIV coinfe

78 of bacterial control that occurs in HIV-Mtb coinfected macrophages correlates with reduced GM-CSF se

79 cted, 169 767 HCV-infected, and 6628 HIV/HCV-coinfected male veterans aged 40-75 years.

80 scued in IFN-gamma-deficient or in TH2 phase coinfected mice demonstrating the key role of this cytok

81 Furthermore, coinfected mice exhibited significantly more airspace ne

82 ific CD8 T cells adoptively transferred into coinfected mice recapitulated the spectrum of helminth-i

83 Bronchoalveolar lavages (BALs) from coinfected mice showed rapid bacterial proliferation 4 t

84 infection with Clostridioides difficile, we coinfected mice that were colonized with ampicillin-resi

85 ive against gonorrhea in gonorrhea/chlamydia-coinfected mice.

86 d HIV-1 infection and dissemination in HSV-2-coinfected mice.

87 ining lymph nodes was detected only in HSV-2-coinfected mice.

88 the groundwork to achieve HCV elimination in coinfected MSM.

89 by ICD-9 codes were used to identify HIV/HBV coinfected (n = 144) and HBV monoinfected (n = 225) pati

90 We coinfected NHBE cells with NAI-susceptible and -resistan

91 an immunodeficiency virus-coinfected (TB/SIV-coinfected) nonhuman primates.

92 In HIV/HCV genotype 1/4-coinfected null responders, a 24-week regimen combining

93 Coinfected participants had lower mean z scores for trab

94 ofosbuvir-based DAA therapy to treat HIV/HCV-coinfected participants pre- or post-liver transplant (L

95 143 HIV/HBV-coinfected participants with detectable HBV DNA were ide

96 autotaxin levels in HCV-infected and HCV-HIV-coinfected participants, compared with uninfected partic

97 rticipants and with Mac2BP levels in HCV-HIV-coinfected participants, while in HIV-infected individua

98 e used a Markov Model to simulate HIV and TB coinfected patient care in LMICs using both publicly ava

99 iffer for HIV-singly (19.0 +/- 0.4 years) or coinfected patients (20.2 +/- 0.6 years) presenting VL<5

100 for HIV-monoinfected (19.0 +/- 0.4 years) or coinfected patients (20.2 +/- 0.6 years) presenting with

101 , all-oral, pan-GT HCV treatment for HIV-HCV coinfected patients across a broad range of ARV regimens

102 HIV/HCV-coinfected patients and HCV-monoinfected patients with a

103 ssful cART is able to normalize survival for coinfected patients and should be introduced for all coi

104 ssful cART is able to normalize survival for coinfected patients and should be introduced for all coi

105 ficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic compli

106 gents has dramatically improved outcomes for coinfected patients as sustained virologic response rate

107 itoring could be reduced in monoinfected and coinfected patients by estimating the probability of mai

108 Cirrhotic HIV/HCV-coinfected patients enrolled in the French National Agen

109 HCV-HIV coinfected patients exhibit rapid progression of liver d

110 640 HIV/HCV-coinfected patients fulfilling the following criteria we

111 Among patients with pVL >50 copies/mL, coinfected patients had a shorter survival time (8.4 +/-

112 Among patients with VL >50 copies-mL, coinfected patients had a shorter survival time (8.4 +/-

113 Deceased coinfected patients had higher initial CD4 count (417 +/

114 Deceased coinfected patients had higher initial CD4 count (417+/-

115 apacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated.

116 Mycobacterium tuberculosis (Mtb) and HIV in coinfected patients has profoundly impacted global morta

117 n well-selected HCV-monoinfected and HIV-HCV-coinfected patients in a real-world setting.

118 r SVR in a representative cohort of Canadian coinfected patients in clinical care.

119 the pathobiology of liver disease in HCV-HIV coinfected patients in the directly acting antiviral era

120 pected to further simplify the management of coinfected patients in the transplant setting.

121 sk factor for all-cause mortality in HIV-HCV-coinfected patients independently of liver fibrosis and

122 nalyzed HCV treatment outcomes among 255 HCV coinfected patients initiating DAAs between February 201

123 r (OPrD) +/- RBV in HIV/HCV genotype 1 (GT1)-coinfected patients initiating HCV therapy in clinical p

124 Our data suggest that eradication of HCV in coinfected patients is associated not only with a reduct

125 Timely ART initiation in all coinfected patients is crucial.

126 rsening drug-induced liver injury challenges coinfected patients on antiretroviral therapy (ART) init

127 A proportion of HIV/HBV-coinfected patients on long-term lamivudine-containing A

128 HCV GT1/HIV-1 coinfected patients on stable DRV-containing ART achieve

129 icacy and safety of OBV/PTV/r + DSV + RBV in coinfected patients on stable, DRV-containing antiretrov

130 Consistently, platelets from coinfected patients presented defective secretion of the

131 randomized, open-label ALLY-2 study, HIV-HCV-coinfected patients received 8 or 12 weeks of once-daily

132 munodeficiency virus (HIV)-tuberculosis (TB) coinfected patients receiving concomitant treatment for

133 argue for the prescription of HCV therapy in coinfected patients regardless of fibrosis stage.

134 Over a 2-year period, only 36.0% of HIV/HBV coinfected patients seen in HIV practices completed HCC

135 In patients with serial samples, only MRSA-coinfected patients showed time-dependent increases in a

136 Nevertheless, coinfected patients still have a higher mortality risk a

137 oad and fewer unrelated infections in HIV/TB coinfected patients suggests a more complex interaction

138 , and D-dimer (P = .0444) were also found in coinfected patients than in HIV-positive/CMV-negative su

139 For the 4 studies of HIV/HCV coinfected patients the pooled recurrence rate was 32.02

140 50 copies/mL) is able to improve survival of coinfected patients to levels observed for those monoinf

141 We included adult VL-HIV coinfected patients treated for VL and discharged cured

142 V) reactivation has been reported in HBV-HCV-coinfected patients treated with DAAs.

143 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with interferon (IFN) and ri

144 In coinfected patients undergoing TDF, qHBcrAg/qAnti-HBc co

145 The risk of VL relapse in coinfected patients was high, particularly in those not

146 SVR rates in HIV/HCV GT1-coinfected patients were high.

147 HBV-coinfected patients were more likely to have significant

148 However, in the modern era, 35% of HBV-coinfected patients were not receiving tenofovir.

149 reated human immunodeficiency virus (HIV)-TB coinfected patients were observed.

150 man immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 week

151 LS at SVR for liver complications in HIV/HCV-coinfected patients with advanced fibrosis treated with

152 apy predicts the clinical outcome of HIV/HCV-coinfected patients with advanced fibrosis.

153 deficiency virus (HIV) and hepatitis C (HCV) coinfected patients with advanced liver disease.

154 ficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients with cirrhosis have long been consid

155 D4 cell counts >300 cells/microL and HIV/HCV-coinfected patients with counts >350 cells/microL.

156 vasive steatosis biomarkers to help identify coinfected patients with higher mortality risk.

157 ial count, this rate was lower, but 97.6% of coinfected patients with initial counts >350 cells/micro

158 rtunity to transform the outcomes of HIV/HCV-coinfected patients with liver complications.

159 te was 2.1 persons-year (76 deaths, 53 among coinfected patients).

160 te was 2.1 person-years (76 deaths, 53 among coinfected patients).

161 between dengue-infected and HIV plus dengue-coinfected patients, plasma levels of the platelet-deriv

162 ed patients and should be introduced for all coinfected patients, regardless CD4 count.

163 ed patients and should be introduced for all coinfected patients, regardless of CD4 cell count.HIV/hu

164 Among HIV/HCV-coinfected patients, statin initiators had lower risks o

165 and biomarkers of bone remodeling in HIV/HCV coinfected patients.

166 is regimen may lead to high failure rates in coinfected patients.

167 us (HCV) genotype 1 (GT1) treatment in HIV-1 coinfected patients.

168 buvir for acute genotype 1 or 4 HCV in HIV-1-coinfected patients.

169 /microL in 5.7% of monoinfected and 11.1% of coinfected patients.

170 monoinfected and 96.4% (27 of 28) in HIV-HCV-coinfected patients.

171 high virologic efficacy in cirrhotic HIV/HCV-coinfected patients.

172 za virus reassortants can arise in naturally coinfected patients.

173 d regimens for HBV should be prioritized for coinfected patients.

174 ; (3) human immunodeficiency virus (HIV)/HCV coinfected patients.

175 s by antiretroviral (ARV) regimen in HIV-HCV-coinfected patients.

176 approval, small trials were done in HIV-HCV coinfected patients.

177 ese results suggest caution in transplanting coinfected patients.

178 PAVIH, a French nationwide cohort of HIV-HCV-coinfected patients.

179 ay increase the risk for HBV reactivation in coinfected patients.

180 nfection is believed to decrease survival of coinfected patients.

181 ency of liver function monitoring for HIV-TB coinfected patients.

182 ency of liver function monitoring for HIV-TB coinfected patients.Post hoc analysis of the Starting An

183 at under current strategies, at least 31 000 coinfected people still require treatment for onchocerci

184 10 predicted HBV reactivation in a cohort of coinfected people taking DAAs.

185 cccDNA transcription is reduced in HIV/HBV coinfected people with longer antiviral duration.

186 Treating a random selection of 51% of coinfected persons at baseline decreased the risk by 1.9

187 tudinally: 7 HCV-monoinfected and 12 HIV/HCV-coinfected persons before and after treatment for HCV, 1

188 Monocyte exosomes from coinfected persons increased in microRNA (miR)-19a, miR-

189 Initiation of ART in HIV/HSV-2-coinfected persons is associated with a transient increa

190 eated human immunodeficiency virus (HIV)/HCV coinfected persons is unclear.

191 -2.8% to .6%), with 51% (95% CI, 38%-59%) of coinfected persons receiving DAAs.

192 ficiency virus (HIV)-hepatitis C virus (HCV)-coinfected persons than HIV-monoinfected persons.

193 The 10-year risk difference of treating all coinfected persons with DAAs compared with no treatment

194 we isolated >1100 hepatocytes from 5 HIV/HBV coinfected persons with increasing exposure to HBV antiv

195 plasma HIV-1 viral load (VL) in HIV-1/HSV-2 coinfected persons, and this was proposed to be due to a

196 rpes simplex virus type 2 (HSV-2) in HIV/HSV-coinfected persons, may sustain HIV tissue reservoirs by

197 nd neopterin were decreased in HCV mono- and coinfected persons.

198 than by the class of anchor agent in HIV-HCV-coinfected persons.

199 nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.

200 representing approximately 23% of the total coinfected population in care in Canada.

201 als (DAAs) in predominantly minority HIV/HCV coinfected populations.

202 ent for age, or longitudinal observations in coinfected populations.

203 a role in protection against cCMV in HIV/CMV-coinfected populations.

204 lthough allograft loss was higher in HIV/HCV coinfected recipients transplanted at enrolling (HR 2.64

205 nt outcomes were superior to HCV+ or HIV/HCV coinfected recipients.

206 we show that rhesus macaques experimentally coinfected simultaneously with ZIKV and DENV-2 demonstra

207 f 106 human immunodeficiency virus (HIV)/HBV-coinfected subjects maintained on lamivudine, as well as

208 ted with slower HIV-1 disease progression in coinfected subjects.

209 T using TB and simian immunodeficiency virus-coinfected (TB/SIV-coinfected) nonhuman primates.

210 Trabecular volumetric BMD was lower in coinfected than in HCV- or HIV-monoinfected participants

211 S. pneumoniae serotype (ST) 6A or 8 and then coinfected them with mouse-adapted H1N1 influenza A viru

212 sought to determine its efficiency in a host coinfected through transmission.

213 o-platelet ratio index [APRI]) among HIV-HCV-coinfected users of modern protease inhibitor (PI)- and

214 45.9% of HCV-infected, and 33.8% of HIV/HCV-coinfected veterans had an indication for statin therapy

215 Nine hundred ninety-six HIV/HCV GT1-coinfected veterans initiated therapy: 757 LDV/SOF, 138

216 inical Case Registry to identify HIV/HCV GT1-coinfected veterans initiating 12 weeks of LDV/SOF +/- R

217 of HCV-infected, 49.1% and 58.5% of HIV/HCV-coinfected veterans recommended).

218 ross-sectional analysis of 6032 (16% HIV/HCV coinfected) Veterans Aging Cohort Study participants enr

219 .57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27 in HIV-monoinfected patients.

220 berculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifamp

221 otal of 279 patients (62% of whom were HIV-1 coinfected) were recruited.

222 ptible pneumococci survive Cm treatment when coinfected with a CAT-expressing strain.

223 to carry out a full replication cycle unless coinfected with a full-length virus.

224 Nonhuman primates (NHPs) coinfected with a mutant simian immunodeficiency virus (

225 Thirteen (56%) were coinfected with a simian foamy virus known to be acquire

226 Sclerotinia sclerotiorum isolate 328 was coinfected with a strain of Sclerotinia sclerotiorum end

227 actinomycetemcomitans was more abundant when coinfected with allopatric than with sympatric microbes,

228 dren with lower respiratory viral infections coinfected with bacteria had elevated levels of neutroph

229 V, present latently in B cells, which may be coinfected with both viruses.

230 CE Persons with HIV infection are frequently coinfected with chronic herpesviruses, which periodicall

231 Most people living with HIV (PLWH) are coinfected with cytomegalovirus (CMV).

232 In Southeast Asia, people are often coinfected with different species of malaria (Plasmodium

233 Host individuals are often coinfected with diverse parasite assemblages, resulting

234 1 patients, of which at least 9 (42.9%) were coinfected with EBOV.

235 opathogenesis, chickens were monoinfected or coinfected with either virulent M. gallisepticum strain

236 iated herpesvirus (KSHV) and 86% of PELs are coinfected with Epstein-Barr virus (EBV).

237 the etiologic agent, and ~80% of tumors are coinfected with Epstein-Barr virus (EBV).

238 adults infected with HTLV-1, either alone or coinfected with HBV.

239 Both HEV-positive cases were coinfected with HBV.

240 Real world data on patients coinfected with HCV and HIV treated with SOF-based regim

241 dy of liver fibrosis progression in patients coinfected with HCV and HIV, using the well-characterize

242 and provided high rates of SVR12 in patients coinfected with HCV and HIV-1.

243 nant women monoinfected with HCV (n = 17) or coinfected with HCV and human immunodeficiency virus (HI

244 ect has been little investigated in patients coinfected with HCV and human immunodeficiency virus (HI

245 However, outcomes among HIV+ LT recipients coinfected with HCV remain concerning and motivate futur

246 munodeficiency virus (HIV)-infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses ar

247 Those with prior malignancies or coinfected with hepatitis B or human immunodeficiency vi

248 Treatment of patients coinfected with hepatitis C and human immunodeficiency v

249 l cohort study (eight countries), 37 (6%; 32 coinfected with hepatitis C virus [HCV] and five with he

250 A total of 1092 HIV-infected patients (51% coinfected with hepatitis C virus) were included.

251 scription opioid oxymorphone, and 92.3% were coinfected with hepatitis C virus.

252 Among patients coinfected with hepatitis C, aRR of mortality at 5 years

253 placebo-controlled trial among 3408 persons coinfected with HIV and herpes simplex virus type 2.

254 of 84 DENV-infected patients of whom 29 were coinfected with HIV under virological control.

255 All five subjects were coinfected with HIV-1 and a closely related strain of HC

256 Children coinfected with HIV-1 had higher levels of TNF-alpha and

257 5A inhibitor velpatasvir for HCV in patients coinfected with HIV-1.

258 reviously treated patients, all of whom were coinfected with HIV-1.

259 V-infected patients were included, 667 (64%) coinfected with HIV.

260 ls with latent tuberculosis infection (LTBI) coinfected with HIV.

261 nd specificity with samples from 69 patients coinfected with HIV.

262 Human immature DCs coinfected with HIV/Mtb had decreased expression of huma

263 IV acquisition by hCD4/R5/cT1 mice vaginally coinfected with HSV-2 could be completely prevented in a

264 We matched 149 patients coinfected with HTLV-1 (cases) by age at HIV diagnosis a

265 In a longitudinal cohort of women coinfected with human immunodeficiency virus (HIV) and h

266 er fibrosis progresses faster in individuals coinfected with human immunodeficiency virus (HIV) and h

267 e antigen (HBeAg) seroclearance in patients coinfected with human immunodeficiency virus (HIV) and h

268 was determined longitudinally among 96 women coinfected with human immunodeficiency virus (HIV), herp

269 ffective these drugs will be for individuals coinfected with human immunodeficiency virus (HIV)-HCV.

270 or hepatitis C virus (HCV) excluded patients coinfected with human immunodeficiency virus (HIV).

271 ects of THC on fibrosis progression in women coinfected with human immunodeficiency virus (HIV)/HCV e

272 rosis progression in a large cohort of women coinfected with human immunodeficiency virus (HIV)/HCV.

273 HCV within-host evolution from 4 individuals coinfected with human immunodeficiency virus 1 (HIV-1).

274 epatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV

275 tuberculosis infection, especially in women coinfected with human immunodeficiency virus; (2) evalua

276 ue specimens were collected from individuals coinfected with KSHV and HIV.

277 single virions released from cells that were coinfected with M tagged with enhanced green fluorescent

278 Chickens coinfected with M. gallisepticum R(low) followed by LPAI

279 ation capacity were compared across children coinfected with MRSA or methicillin-susceptible S. aureu

280 In this study, nonhuman primates were coinfected with Mtb and simian immunodeficiency virus (S

281 vo in tissues free of HSV-2 but endogenously coinfected with other HHVs.

282 t adults and adolescents, including patients coinfected with other sexually transmitted infections (s

283 ctive effect in SIV-infected African monkeys coinfected with pegiviruses, possibly because SIV causes

284 usly shown that 11 patients became naturally coinfected with seasonal H1N1 (A/H1N1) and pandemic H1N1

285 Following treatment, animals were coinfected with simian immunodeficiency virus to assess

286 led chronic genotype 1a HCV-infected persons coinfected with suppressed HIV: 5 of 6 treatment-naive e

287 Patients coinfected with syphilis and human immunodeficiency viru

288 h the human immunodeficiency virus (HIV) are coinfected with the hepatitis C virus (HCV) due to share

289 he ongoing outbreak in Sierra Leone, 13 were coinfected with the immunomodulatory pegivirus GB virus

290 In the UTI model, mice coinfected with the two species exhibited higher urine p

291 etions were self-collected by nine HIV/HSV-2-coinfected women during ART for 28 days to establish sub

292 Subclinical HSV shedding in HIV/HSV-coinfected women during ART may sustain HIV tissue reser

293 Among 575 HIV/HCV-coinfected women followed for a median of 11 (interquart

294 red with healthy reference patients, HIV/HCV-coinfected women had decreased tibial trabecular volumet

295 netics (PK) study assessed DMPA among HIV/TB coinfected women on an efavirenz-based antiretroviral tr

296 Among 686 HIV/HCV-coinfected women, 46.0% reported no alcohol use; 26.8% r

297 In HIV/HCV-coinfected women, hepatic fibrosis accelerates with repr

298 In this large cohort of HIV/HCV-coinfected women, THC was not associated with progressio

299 on may be different between monoinfected and coinfected women.

300 tter predict fibrosis progression in HIV/HCV-coinfected women.